Authors: Kam Lun Hon, Karen Ka Yan Leung, Felix Oberender, Alexander KC Leung
Categories: Review, acute lung injury, critical care, paediatric acute respiratory distress syndrome, respiratory failure, therapy
Source: Drugs in Context
Doi: 10.7573/dic.2021-1-9
Acute respiratory distress syndrome (ARDS) is a significant cause of mortality and morbidity amongst critically ill children. The purpose of this narrative review is to provide an up-to-date review on the evaluation and management of paediatric ARDS (PARDS).
A PubMed search was performed with Clinical Queries using the key term “acute respiratory distress syndrome”. The search strategy included clinical trials, meta-analyses, randomized controlled trials, observational studies and reviews. Google, Wikipedia and UpToDate were also searched to enrich the review. The search was restricted to the English literature and children.
Non-invasive positive pressure ventilation, lung-protective ventilation strategies, conservative fluid management and adequate nutritional support all have proven efficacy in the management of PARDS. The Pediatric Acute Lung Injury Consensus Conference recommends the use of corticosteroids, high-frequency oscillation ventilation and inhaled nitric oxide in selected scenarios. Partial liquid ventilation and surfactant are not considered efficacious based on evidence from clinical trials.
PARDS is a serious but relatively rare cause of admission into the paediatric intensive care unit and is associated with high mortality. Non-invasive positive pressure ventilation, lung-protective ventilation strategies, conservative fluid management and adequate nutrition are advocated. As there has been a lack of progress in the management of PARDS in recent years, further well-designed, large-scale, randomized controlled trials in this field are urgently needed.
Keywords: acute lung injury, critical care, paediatric acute respiratory distress syndrome, respiratory failure, therapy
Acute respiratory distress syndrome (ARDS) is one of the leading causes of admission into the intensive care unit (ICU).1–3 The syndrome of non-cardiogenic pulmonary oedema and hypoxia also affects children and accompanies significant mortality in paediatric ICU (PICU). Paediatric ARDS (PARDS) is diagnosed by the presence of hypoxia and new chest infiltrate occurring within seven days of a known insult. Hallmarks of ARDS include hypoxemia associated with decreased lung compliance, increased work of breathing and impaired gas exchange. Mortality is often accompanied by multiple organ dysfunction or failure. Like adults, supportive therapies and lung-protective ventilator support remain the mainstay of treatment in children. Paediatric healthcare workers in the non-ICU setting remain unfamiliar with the disease entity. This article provides an up-to-date narrative review on the evaluation, diagnosis and management of PARDS.
A PubMed search was performed in November 2020 with Clinical Queries using the key term “acute respiratory distress syndrome”. The search strategy included clinical trials, meta-analyses, randomized controlled trials, observational studies and reviews published between Jan 2010 and Dec 2020. Google, Wikipedia and UpToDate were also searched to enrich the review. The search was restricted to the English literature and children. The information retrieved was used as a basis for the compilation of the present article.
ARDS was first defined by Ashbaugh et al. in 1967 as ‘adult-type respiratory distress’ for a group of patients with progressive respiratory failure, refractory hypoxemia, decreased functional residual capacity, loss of lung compliance and diffuse infiltration on chest radiography.1–4 In 1994, the American-European Consensus Conference (AECC) formalized the clinical definitions of acute lung injury (ALI) and ARDS. ALI is a disease with acute onset hypoxemia, a partial pressure of oxygen (PaO2) to fraction of inspired oxygen (FiO2) ratio of ≤300, bilateral infiltrates on chest radiographs and a pulmonary artery wedge pressure less than 18 mmHg, and the absence of left atrial hypertension.5 ARDS is a more severe form of ALI and largely shares the same criteria, whereby ARDS occurs when the PaO2/FiO2 ratio is ≤200.5
Subsequently, in 2012, the international consensus criteria for ARDS were updated and became known as the Berlin definition of ARDS, in which the timing of onset is defined (onset within 1 week) and the degree of hypoxemia is subcategorized to mild, moderate and severe depending on the PaO2/FiO2 ratio.6–10 The term ALI was also removed from the Berlin definition to minimize the confusion amongst medical practitioners as the acronym served little to no practical purpose and had become seldom used in any case.11
Although ARDS occurs across all age groups, including children, the AECC and Berlin ARDS definitions have limitations when applied to children due to the difference in hypoxemia measurement and in the aetiology and pathophysiology of ARDS in paediatric patients.12,13 As the presentation of ARDS in children is different from that in adults, the consensus of a formal PARDS definition was reached only in 2015 during the Pediatric Acute Lung Injury Consensus Conference (PALICC).12–14 This latest definition for PARDS is as 6,12,13,15,16
In comparison to the Berlin definition, the PALICC criteria identified more patients with ARDS although there were no differences in clinical outcomes between the groups.6,9,15,16 Nevertheless, the Berlin definition offers no room for stratifying and identifying ‘true’ ARDS patients because there is no re-evaluation of the hypoxemia under a standard ventilator setting in a specific time period under this definition.7,9
PARDS is relatively rare but the incidence is likely under-reported due to the lack of a standardized and reliable definition until the development of the PALICC criteria in 2015. The incidence in the United States, Europe and Australia has been estimated to be 2–12.8/100,000 people per year.18,19 Studies in China, Europe, New Zealand and Australia suggest that ARDS accounts for 1–4% of PICU admissions.11,18,20–22 In addition, studies have reported an increased incidence of ARDS in men in comparison to women and immunodeficiency is a common pre-existing condition leading to an increased risk of developing ARDS.23 The mortality of PARDS in the literature varies from 18% to 63%, depending on the study locations, whilst a recent systematic review and meta-analysis of 2,274 patients concluded that the overall mortality rate in PARDS is of approximately 24%.11,18,24,25 Generally, the mortality of ARDS in children is lower than that in adults but age-dependent differences in respiratory viral infections may contribute to the differences in outcome between children and adults.23,26,27 A 2016 systematic review and meta-analysis showed a low incidence but a high mortality of PARDS and also concluded that both the incidence and mortality of PARDS have not changed over the last two decades although the mortality rate varies depending on the geographic location of studies.28 The incidence and epidemiology of PARDS have been reviewed in recent years by the Pediatric Acute Respiratory Distress syndrome Incidence and Epidemiology (PARDIE) investigators, who describe predictive models for mortality in PARDS using readily available variables from day 0 of PARDS.29–32 These PARDIE models outperform severity of illness scores and demonstrate the utility for composite outcomes and assist with risk stratification for clinical trials.32
ARDS is not a specific disease entity but a clinical syndrome that may be triggered by various pathologies, including trauma, pneumonia and sepsis. As with many other syndromes, the term essentially describes non-cardiogenic pulmonary oedema of various aetiologies. PARDS can be caused by a variety of insults. Depending on whether the lungs are initially affected, the causes can be classified as direct or indirect lung injury. Direct causes of lung injury include pneumonia, aspiration, inhalational lung injury, lung contusion, chest injury and submersion injury. Indirect causes include sepsis, shock, pancreatitis, trauma, cardiopulmonary bypass, transfusion-related ALI, burns and increased intracranial pressure.33–37
On the other hand, lung injury can be secondary to various hyperinflammatory or cytokine release syndromes (CRS). CRS refers to a form of systemic inflammatory response syndrome that can be triggered by a variety of factors such as infections and certain drugs; if severe and acute, it is termed cytokine storm syndrome.2 Hemophagocytic lymphohistiocytosis (HLH), being one of the underlying causes of CRS, refers to a life-threatening disorder of severe excessive inflammation caused by uncontrolled proliferation of activated lymphocytes and macrophages and the secretion of inflammatory cytokines. Nahum et al. reported that 7 of 11 children with HLH with multiple organ failure exhibited ARDS after a diagnosis of HLH had been made.38
ARDS is an acute inflammation of the lung with diffuse alveolar injury and increased vascular permeability with consequent decreased pulmonary compliance, impaired gas exchange and pulmonary hypertension leading to hypoxic respiratory failure.4,39,40 The pathogenesis of ARDS can be divided into three (1) the exudative phase, when the resident alveolar macrophages are activated and potent proinflammatory mediators and chemokines are released, resulting in interstitial and intra-alveolar flooding; (2) the proliferative phase, characterized by provisional matrix formation and restoration of endothelial barrier function; and (3) the fibrotic phase, characterized by the development of interstitial and intra-alveolar fibrosis due to extensive damage to the basement membrane.41
The lung of paediatric patients characteristically differs from that of adults in many aspects, including smaller airways, lower rigidity of the chest wall and lower functional residual capacity.40,42 Most importantly, the major difference between children and adults is that the lungs of children are developing and growing until the attainment of adult height and the pathophysiological responses to infection and injury are therefore fundamentally different.43
ARDS is characterized by tachypnoea, dyspnoea and hypoxemia. The symptomatology of ARDS could begin as early as 2 hours of an inciting event but have been known to take as long as 1–3 days. The signs and symptoms may include shortness of breath, fast breathing, diffuse crackles and tachycardia.44 Other common symptoms include muscle fatigue and general weakness, low blood pressure, and either a dry, hacking or productive cough.44 In severe cases, diaphoresis and cyanosis may be evident. Depending on the underlying aetiology, the clinical features may include fever, chest pain, pleuritic pain, vomiting and abdominal pain.
The diagnosis of PARDS in children is based on the aforementioned diagnostic criteria defined by PALICC in 2015. Studies in adults showed that the Berlin diagnostic criteria for ARDS have a relative low specificity for diagnosing ARDS.45 Furthermore, ARDS is a clinical syndrome without a specific diagnostic test, which can explain why the diagnosis is underrecognized, sometimes delayed or missed altogether.45,46 The early diagnosis and prompt treatment of ARDS and subsequent implementation of treatment strategies are all key to maximizing the chance of survival.45
To define the degree of hypoxemia with the PALICC criteria, both OI or OSI can be used to quantify this in patients with invasive ventilation. Whilst the PaO2/FiO2 or SpO2/FiO2 ratios can be used in patients receiving non-invasive mechanical ventilation with a minimum continuous positive airway pressure of 5 cm H2O,13 OI and PaO2/FiO2 are preferred; OSI and SpO2/FiO2 should only be used if arterial blood gas is not available.13
Radiological imaging has long been a key diagnostic modality for ARDS. Original AECC definitions of ARDS specified that correlative chest X-ray findings were required for diagnosis although the diagnostic criteria have been broadened over time to include computed tomography (CT) findings. Chest imaging of new infiltrates consistent with acute pulmonary parenchymal disease is one of the diagnostic criteria.9,13 However, chest X-rays have limitations in terms of poor interobserver reliability.29,47 A prospective, international observational study in children using the PALICC criteria for ARDS evaluating the independent relationship between chest imaging and mortality revealed that chest X-ray findings of bilateral infiltrates or four quadrants of consolidation are associated with higher mortality but only for children with severe oxygenation impairment (PaO2/FiO2 ratio ≤100).29 Radiographic findings of pulmonary oedema affecting both lungs and unrelated to increased cardiopulmonary vascular pressure may be suggestive of ARDS. CT of the chest, although not routinely performed, may also be helpful in differentiating between atelectasis and consolidation.
Ultrasonography is an easy method for the further assessment of pleural effusions and differentiation between transudative and exudative fluid. Ultrasound findings suggestive of ARDS include anterior subpleural consolidations, the absence or reduction of lung sliding, pleural line abnormalities (an irregular, thickened and fragmented pleural line) and non-homogeneous distribution of B-lines (suggestive of fluid accumulation in the lungs).48 Echocardiography may help exclude cardiogenic oedema and would provide information regarding cardiac contractility, intraventricular volume, pulmonary hypertension and other potential anatomic abnormalities. The routine use of bronchoalveolar lavage is not recommended in ARDS. Bronchoalveolar lavage can be considered for diagnostic and therapeutic purposes in cases where there is no obvious cause of ARDS, or persistent regional areas of atelectasis or when a direct lung injury is suspected.49
Laboratory testing including haematology and blood chemistry would help identify the potential involvement of other organ systems and inform appropriate management strategies. Arterial blood gas analysis should be done, and the severity of hypoxemia or PaO2 should also be determined. Numerous biomarkers have been examined in the literature to support the diagnosis of ARDS; however, no definitive biomarkers or tools with a high quality of predictability have been identified both in terms of predicting mortality or differentiating between cardiogenic pulmonary oedema and ALI or ARDS.50,51 A recent systematic review of biomarkers suggested that angiopoietin 2 and receptor for advanced glycation end products (RAGE) were associated with an increased risk of ARDS development.51 Combining clinical criteria with validated biomarkers may be one way to improve the predictive accuracy of diagnostic tests in the future. It is also important to discriminate ARDS from cardiogenic pulmonary oedema as the two conditions may coexist, which may be challenging in critically ill patients.52
The main management goals are anchored around treating the underlying cause, maintaining adequate oxygenation as well as avoiding secondary lung injury and extra pulmonary complications.42,53,54 Antibiotics or antivirals are useful for ARDS associated with bacterial or viral infections, but are not indicated or useful if ARDS is due to submersion injury. The management of PARDS is challenging as there is no definitive guideline or conclusive clinical evidence to optimize the treatment regimen.55 Contemporary treatment strategies are largely extrapolated from adult studies even though paediatric patients differ from adults in many pathophysiological aspects and only a handful of randomized control trials have been performed on paediatric patient groups. In this regard, children have a more compliant chest wall, higher baseline airway resistance and lower functional residual capacity.40
Early non-invasive positive pressure ventilation (NPPV) can be considered in children with mild PARDS. The continuous level of positive end expiratory pressure (PEEP) can facilitate airway opening, improve alveolar recruitment and improve oxygenation, whilst the additional inspiratory pressure can raise tidal volumes and reduce respiratory effort.56,57 A randomized controlled trial with 50 patients comparing NPPV with a control group showed that heart rate and respiratory rate improved with NPPV and the frequency of endotracheal intubation was also significantly lowered (from 60% to 28%; p=0.045).58 However, NPPV is not recommended for patients with severe hypoxemia.13 Intubation and invasive ventilation is also indicated when there are signs of increased respiratory effort and oxygen requirement, a decreased PaO2/FiO2 ratio or altered levels of consciousness.57
The principle of lung-protective ventilation strategies is to avoid volutrauma and minimize atelectrauma. However, studies on lung-protective ventilation strategies in the paediatric population are limited and most recommendations are based on evidence gathered from adult patients. Robust clinical evidence on the optimal lung-protective strategies in PARDS patients is much needed.
The optimal tidal volume remains a subject of controversy and current practices are usually based on data extrapolated from the studies on adult patients in which volutrauma is found to be associated with lung injury in ventilated adult ARDS patients.59 A retrospective study revealed that ventilation with a higher tidal volume resulted in higher mortality and shorter ventilation-free days.60 A lower tidal volume was independently associated with reduced mortality and an increase in ventilation-free days.60 However, another prospective study showed that a high maximum and median tidal volume resulted in a lower mortality.21 A 2014 systematic review and meta-analysis of eight observational studies showed that there was no significant association between the tidal volume and mortality.61 A recent retrospective analysis conducted in 2019 also reported similar findings with no consistent association between tidal volume adjusted for ideal body weight and outcome, suggesting that tidal volume could be an imprecise parameter for titrating ventilation.62 To date, no further randomized controlled trials are known to have been conducted in order to conclusively assess the effect of tidal volume on the mortality of paediatric patients. In 2015, PALICC made a recommendation using patient-specific tidal volume, which is outlined hereafter. In patients with good lung compliance, a physiological range tidal volume of 5–8 mL/kg of ideal body weight should be applied to preserve the respiratory system compliance. On the other hand, in those with poor lung compliance, a tidal volume of 3–6 mL/kg of ideal body weight should be applied.13,63
Common practice in paediatric mechanical ventilation is often based on personal experiences and adoption from adult and neonatal experience. The European Society for Paediatric and Neonatal Intensive Care initiated a consensus conference of international European experts to provide recommendations in paediatric mechanical ventilation.64 The ARDS Network (ARDSNet) used a PEEP/FiO2 model in many studies. Nevertheless, paediatric intensive care physicians often use less PEEP and higher FiO2 than this model.65 Adequate PEEP is necessary to prevent atelectrauma in patients with ARDS and the PALICC recommend the titration of oxygenation and hemodynamic response with moderately elevated levels of PEEP (10–15 cm H2O) and a PEEP level of greater than 15 cm H2O might be required for severe PARDS.13,65 A multicentre, retrospective analysis of patients with PARDS showed that children who are managed with PEEP lower than recommended by the ARDSNet PEEP/FiO2 model had a higher mortality.65
A retrospective study performed in 2009 reported that high-frequency oscillatory ventilation (HFOV) improved oxygenation in paediatric patients with ARDS.66 However, a separate retrospective observational study in 2014 revealed that HFOV was associated with a longer duration of mechanical ventilation, longer ICU length of stay and higher mortality in children with acute respiratory failure.67 A secondary analysis of a prospective cluster-randomized trial in 2016 reported that early use of HFOV was associated with a longer duration of mechanical ventilation but not with mortality when compared with conventional ventilation.68 A 2016 systematic review including 10 randomized controlled trials comparing HFOV with conventional mechanical ventilation on both adults and children with ARDS found that HFOV was not associated with lower 30-day mortality.66 The evidence available does not support the use of HFOV as a first-line strategy in patients undergoing mechanical ventilation for ARDS. Later, a randomized controlled study further compared HFOV versus conventional mechanical ventilation in PARDS and demonstrated that HFOV had a superior advantage in improving oxygenation but no significant mortality improvement.69 Nevertheless, PALICC suggested the use of HFOV for patients with moderate-to-severe ARDS in cases where the plateau airway pressure exceeds 28 cm H2O and in the absence of clinical evidence of reduced chest wall compliance.13,63
Although the practice appears to be conceptually sound, partial liquid ventilation was not found to be associated with a decrease in 28-day mortality in a randomized trial.70 No further studies have been conducted. On this basis, PALICC does not recommend the use of partial liquid ventilation on PARDS.13
Inhaled nitric oxide (iNO) is a selective pulmonary vasodilator in improving V/Q matching and has been shown to improve oxygenation; however, there is no strong evidence to support a reduction in mortality and, in fact, may actually be harmful.71 A prospective RCT of 55 paediatric patients with ARDS showed a significant reduction in duration in mechanical ventilation and a greater rate of extracorporeal membrane oxygenation-free survival.72 PALICC does not recommend the routine use of iNO for PARDS but it can be considered in patients with documented pulmonary hypertension, severe right ventricular dysfunction, or as a rescue or bridge to extracorporeal life support.13,63 Further studies are required to study the potential effects of iNO such as platelet aggregation inhibition and effects on the immune system and immunoregulations.73
In a randomized blinded trial conducted by Wilson et al. in 2005, the use of surfactants was shown to significantly improve oxygenation and decrease mortality in patients with ARDS.74 In 2013, the same group of investigators conducted a randomized controlled trial with 110 subjects with ARDS and demonstrated that there were no benefits in survival.75 The adverse events related to the use of surfactants can include transient hypoxia, bradycardia and leukopenia. In aggregate, surfactants are generally considered as non-efficacious for the treatment of ARDS in children.63
Prone positioning might improve oxygenation in patient with ARDS by recruitment of collapsed alveoli of the dorsal lung regions, thereby improving the homogeneity of ventilation and ventilation/perfusion matching.76 A 2012 systematic review of 24 studies with 581 participants demonstrated that the prone position was associated with significantly improved oxygen saturation, arterial oxygen and thoracoabdominal synchrony with no reported side effects.77 These results were contrary to the findings from a randomized controlled trial conducted in 2005 by Curley et al. which suggest that the prone position did not significantly lower ventilation-free days or mortality or overall health function.78 Prone positioning is not recommended as a routine therapy for ARDS treatment by PALICC but it can be considered in cases of severe PARDS.13,63 In the meantime, paediatric patients in the Prone and Oscillation Pediatric Clinical Trial (PROSpect) are being recruited to address the issue surrounding the uncertainty regarding the role and optimal management of HFOV and prone position for PARDS.79
Extracorporeal membrane oxygenation (ECMO) can potentially provide rescue oxygenation and ventilation, preventing ventilator-induced lung injury and multiorgan failure.80 According to the Extracorporeal Life Support Organization (ELSO) criteria, severe respiratory failure is defined as a sustained PaO2/FiO2 ratio of <60–80 or an OI of >40, a lack of response to conventional ventilation and rescue therapy (e.g. HFOV, iNO), and elevated ventilator pressure.81 Based on the data available on the ELSO registry of neonates and children with respiratory failure requiring ECMO support, the survival rate of neonates (87%) is higher than in children (72%), although these figures represent the overall survival of respiratory failure and are not specific to PARDS.82 There are no randomized trials assessing the efficacy of ECMO in PARDS; however, a paired cohort study of 122 matched children with acute respiratory failure with and without ECMO showed that there were no differences in the in-hospital mortality, PICU or ventilator-free days between two groups.83 Patient selection in the use of ECMO is crucial as the range of clinical outcomes can vary widely; however, there is no well-defined criteria for children with PARDS who would manifestly benefit from ECMO.80 PALICC recommends that ECMO can be considered in paediatric patients with severe PARDS when other treatment strategies demonstrably fail to maintain adequate gas exchange.13,63
Non-invasive monitoring of oxygenation has become a standard procedure in critical care. Both transcutaneous pO2 (tcpO2) monitors and pulse oximeters (SpO2) should be familiar to those using these devices in infants.84,85 Measurements of tcpO2 are influenced by skin thickness, sensor temperature, amount of contact gel used and the state of peripheral perfusion. Pulse oximeters require careful sensor placement and adequate pulse pressures (>20 mmHg/2.7 kPa). They are extremely prone to motion artifact. TcpO2 monitoring is currently being replaced by pulse oximetry, which does not measure oxygen concentration in plasma but rather the proportion of haemoglobin molecules in arterial blood that are loaded with oxygen. Pulse oximeters are easier to use than tcpO2 monitors and provide immediate information about arterial oxygenation.84,85 One advantage of transcutaneous monitoring is that tcpCO2 monitoring can be simultaneously estimated, which is superior to end tidal CO2 monitoring in paediatric patients aged >4 years with respiratory failure.86 Application of this technique should be useful by decreasing the need for repeated and sometimes painful arterial blood gas analysis and the continuity of assessment should facilitate proactive ventilator manipulations.
PALICC recommended that, for mild PARDS with PEEP <10 cm H2O, the SpO2 goal should generally be 92–97%. For those with more severe PARDS with PEEP >10 cm H2O, permissive hypoxemia with an SpO2 of 88–92% should be considered after PEEP optimization. 13,42,87,88 The use of permissive hypoxemia is cautioned against in those with acute intracranial pathology and clinically important pulmonary hypertension. When oxygen saturations are maintained <92%, PALICC recommended the monitoring of central venous saturation and markers of oxygen delivery.13,63,87 Ventilatory approaches should provide adequate tissue/organ oxygenation whilst minimizing oxygen toxicity and ventilator-induced lung injury. PALICC also recommended permissive hypercapnia as a management strategy to minimize ventilator-induced lung injury for patients with moderate-to-severe PARDS.13,63,87 Low-VT tidal volume, pressure-limited ventilation with permissive hypercapnia may improve ARDS outcome.63,89,90 A pH range of 7.15–7.30 was also recommended within the use of lung-protective guidelines. Exceptions to the use of permissive hypercapnia include severe pulmonary hypertension, intracranial hypertension, select congenital heart lesions and significant ventricular dysfunction with hemodynamic instability.
Appropriate fluid management is critical in patients with PARDS as increased mortality and high cumulative fluid balance are associated with fewer ventilator-free days, worse oxygenation, increased mortality and acute kidney injury in children with PARDS.28,91,92 PALICC suggests a goal-directed fluid management approach after the initial stabilization of the patient and titration to maintain adequate intravascular volume, end-organ perfusion and optimal oxygen delivery, all whilst aiming to avoid fluid overload.13
Patients with ARDS are particularly susceptible to malnutrition as these patients are often in a hypercatabolic state because critical illness is associated with an increased basal metabolic rate and protein catabolism. Malnutrition might lead to loss of lean body mass, muscle weakness, and loss of respiratory and cardiac muscle function.93 Adequate protein intake and nutrition were found to be associated with better survival in children with PARDS.74,93 Nutrition plans should be tailored to meet the patient’s metabolic demand, whilst enteral nutrition is preferred over parenteral nutrition if tolerated.13 Despite having target calorie and protein requirements, many critically ill children do not achieve satisfactory levels even at the end of a week in PICU.94 The preferred mode of nutrition delivery is early enteral nutrition. Immunonutrition has not conclusively demonstrated benefit in terms of mortality or reduced length of stay in PICU. Immunonutrients in PARDS may include omega-3 fatty acids, arginine, glutamine and vitamin D, although these are yet to be formally recommended.
Theoretically, corticosteroids can dampen the immune and inflammatory systems, thereby minimizing the disease severity of ARDS.95 However, there is a degree of controversy around the use of corticosteroids in PARDS.63 In a double-blinded, placebo-controlled, randomized clinical trial, there was no difference in the duration of mechanical ventilation, ICU stay, hospital stay and mortality between steroid and placebo groups in children with ARDS.96 Another prospective cohort study showed that corticosteroid exposure of more than 24 hours was independently associated with longer duration of ventilation in survivors, even after adjusting for immunocompromised status, severity of illness, oxygenation index and number of organ failures.97 Based on the full body of evidence, the routine use of corticosteroids in PARDS is not recommended.13,98
Children with ARDS subjected to mechanical ventilation often require sedative or analgesic agents to facilitate synchronization with the ventilator and decrease anxiety or pain.63,99 Curley et al. conducted a cluster-randomized trial on 2449 children with ARDS and the use of sedation did not shorten the duration of mechanical ventilation. Patients with sedation were reported to have more postextubation stridor and more days with a high pain score and agitation.100 PALICC guidelines suggest that sedation should be titrated to a minimal yet effective level to facilitate effective ventilation.13
Complications of ARDS may include barotrauma (volutrauma), nosocomial infection, atelectasis, pulmonary embolism, pulmonary fibrosis and ventilator-associated pneumonia.44 Dysfunction of other organ systems may also be observed, including right ventricular dysfunction, pulmonary hypertension, gastrointestinal complications (stress ulcer and bacterial translocation), hypoxic brain damage, deep vein thrombosis, myocardial dysfunction, acute kidney failure, fluid retention, catabolic malnutrition and electrolyte abnormalities.44,101
The overall prognosis of ARDS is poor, with high relative mortality rates of approximately 40%.63,102 Studies on the long-term outcome of PARDS patients are limited in the literature, most of which are small case series. Based on reports on adult and paediatric patients, long-term sequalae in ARDS survivors include prolonged pulmonary dysfunction, neuromuscular weakness, nutritional deficits, anxiety, depression and post-traumatic stress disorders.103,104 At the same time, exercise limitations, physical and psychological sequelae, decreased physical quality of life, and increased costs and use of healthcare services are also important sequelae of ARDS.105 PALICC recommend screening for pulmonary function abnormalities within 1 year after discharge and those with pulmonary function deficits should be followed up by a paediatric pulmonologist.13
PARDS is a serious but relatively uncommon cause of PICU admission that is associated with high mortality. However, there is a limited amount of evidence specific to paediatric patients to support the efficacy of most of the clinical practices. The recent development of the paediatric-specific definitions of PARDS in 2015 should facilitate the diagnosis, treatment and research in PARDS. Advances are being made in the management of PARDS in areas including early NPPV, lung-protective ventilation strategies, conservative fluid management and adequate nutritional support, all of which are supported by evidence of efficacy. The use of iNO, HFOV, prone positioning and corticosteroids remain controversial. Extracorporeal membrane oxygenation can be considered as a rescue therapy. A deeper understanding of the pathophysiological mechanism of PARDS can potentially facilitate the development of novel therapeutic interventions to prevent or modulate lung injury as well as targeted therapies.43 In any case, more well-designed, large-scale, multicentre prospective randomized controlled trials on PARDS are urgently needed.
None.